Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Non-Current Deffered Revenue (2017 - 2023)

BeOne Medicines (BEIGF) has disclosed Non-Current Deffered Revenue for 6 consecutive years, with $300000.0 as the latest value for Q4 2023.

  • Quarterly Non-Current Deffered Revenue fell 99.29% to $300000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $300000.0 through Dec 2023, down 99.29% year-over-year, with the annual reading at $300000.0 for FY2023, 99.29% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2023 was $300000.0 at BeOne Medicines, roughly flat from $300000.0 in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $220.3 million in Q4 2021, with the low at $300000.0 in Q3 2023.
  • Average Non-Current Deffered Revenue over 4 years is $81.6 million, with a median of $52.3 million recorded in 2021.
  • The sharpest move saw Non-Current Deffered Revenue skyrocketed 186.77% in 2022, then crashed 99.8% in 2023.
  • Over 4 years, Non-Current Deffered Revenue stood at $8.2 million in 2019, then surged by 2573.41% to $220.3 million in 2021, then tumbled by 80.92% to $42.0 million in 2022, then plummeted by 99.29% to $300000.0 in 2023.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $300000.0, $300000.0, and $24.3 million for Q4 2023, Q3 2023, and Q2 2023 respectively.